TransMedics Group, Inc.

NasdaqGM TMDX

TransMedics Group, Inc. Receivables for the quarter ending September 30, 2024: USD 90.13 M

TransMedics Group, Inc. Receivables is USD 90.13 M for the quarter ending September 30, 2024, a 48.59% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

TransMedics Group, Inc. Receivables for the quarter ending September 30, 2023 was USD 60.65 M.
TransMedics Group, Inc. Receivables for the quarter ending September 30, 2021 was USD 4.15 M, a -32.42% change year over year.
TransMedics Group, Inc. Receivables for the quarter ending September 30, 2020 was USD 6.14 M, a -5.01% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NasdaqGM: TMDX

TransMedics Group, Inc.

CEO	Dr. Waleed H. Hassanein M.D.
IPO Date	May 2, 2019
Location	United States
Headquarters	200 Minuteman Road
Employees	584
Sector	Healthcare
Industries Biotechnology 3D Printing Hospitals & Clinics Medical Instruments Pharmaceuticals Pollution Treatment Telehealth

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Key trends

Past 5 years